Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 2, 2007, Pages 174-182

  Tozzi, Valerio ^a   Balestra, Pietro ^a   Bellagamba, Rita ^a   Corpolongo, Angela ^a   Salvatori, Maria Flora ^a   Visco Comandini, Ubaldo ^a   Vlassi, Chrysoula ^a   Giulianelli, Marinella ^a   Galgani, Simonetta ^b   Antinori, Andrea ^a   Narciso, Pasquale ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Highly active antiretroviral therapy; HIV dementia; HIV infection; Neurocognitive impairment

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL CONCENTRATION; MENTAL FUNCTION; MULTIVARIATE ANALYSIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 34249895916     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318042e1ee     Document Type: Article

References (29)

1. Navia BA, Price RW. The acquired immunodeficiency syndrome dementia complex as the presenting or sole manifestation of human immunodeficiency virus infection. Arch Neurol. 1987;44:65-69.
2. American Academy of Neurology. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778-785.
3. Albert SM, Marder K, Doonief G, et al. Neuropsychologic impairment in early HIV infection. A risk factor for work disability. Arch Neurol. 1995;52:525-530.
4. Tozzi V, Balestra P, Galgani S, et al. Neurocognitive performance and quality of life in patients with HIV infection. AIDS Res Hum Retroviruses. 2003;19:643-652.
5. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59:1944-1950.
6. Tozzi V, Balestra P, Serraino D, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res Hum Retroviruses. 2005;21:706-713.
7. Sidtis JJ, Gatsonis C, Price RW, et al, and the AIDS Clinical Trial Group. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol. 1993;33:343-349.
8. Price RW, Yiannoutsos CT, Clifford DB, et al. Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium Study Team. AIDS. 1999;13:1677-1685.
9. Ferrando S, Van Gorp W, McElhiney M, et al. Highly active antiretroviral treatment in HIV infection: benefits of neuropsychological function. AIDS. 1988;12:F65-F70.
10. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV 1-associated neurocognitive impairment. AIDS. 1999;13:1889-1897.
11. Gisslen M, Svennerholm B, Norkrans G, et al. Cerebrospinal fluid and plasma viral load in HIV-infected patients with various antiretroviral regimens. Scand J Infect Dis. 2000;32:356-369.
12. Tashima KT, Caliendo AM, Ahmad M, et al. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1 infected patients receiving combination therapy. J Infect Dis. 1999;180:862-864.
13. Letendre SL, McCutchan JA, Childers ME, et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol. 2004;56:416-423.
14. Saktor N, McDermott MP, Marder K, et al. HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol. 2002;8:136-142.
15. Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17:1539-1545.
16. Dougherty RH, Skolasky RL, McArthur JC. Progression of HIV-associated dementia treated with HAART. AIDS Read. 2002;12:69-74.
17. Masliah E, De Teresa RM, Mallory RE, et al. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS. 2000;14:69-74.
18. Neuenburg JK, Brodt HR, Herndier BG, et al. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:171-177.
19. Lezak MD. Neuropsychological Assessment. New York: Oxford University Press; 1983.
20. Spinnler H, Tognoni G. Standardizzazione e taratura italiana di test neuropsicologici [in Italian]. Ital J Neurol Sci. 1987;6(Suppl 8):49-54.
21. Tozzi V, Balestra P, Lorenzini P, et al. Prevalence and risk factors for HIV-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol. 2005;11:265-273.
22. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157:3-10.
23. Larussa D, Lorenzini P, Cingolani A, et al. Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. AIDS Res Hum Retroviruses. 2006;22:386-392.
24. Cysique LA, Maruff P, Brew B. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology. 2006;66:1447-1450.
25. Abdulle S, Hagberg L, Svennerholm B, et al. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS. 2002;16:2145-2149.
26. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology. 2004;63:2084-2090.
27. McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4:543-555.
28. Mortimer JA, Borenstein AR, Gosche KM, et al. Very early detection of Alzheimer neuropathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol. 2005;18:218-223.
29. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Suppl 1):S19-S25.